Mycofenolzuur Accord (Mycophenolic Acid)

Mycofenolzuur Accord (mycophenolic acid) is used in immunosuppressive therapy to inhibit lymphocyte proliferation.

• Renal transplant rejection: helps prevent acute and chronic rejection in kidney transplant recipients.
• Cardiac transplant rejection: reduces the risk of graft rejection after heart transplantation.
• Hepatic transplant rejection: supports maintenance of graft function in liver transplant patients.
• Lupus nephritis: contributes to disease control in patients with systemic lupus erythematosus affecting the kidneys.

• Mycophenolic acid selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanine nucleotides. By reducing guanine nucleotide pools, it impairs DNA synthesis and proliferation of activated T and B lymphocytes, while sparing other cell types that can utilize salvage pathways, thereby providing targeted immunosuppression.

Mycofenolzuur Accord may be associated with a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Hypertension: elevated blood pressure requiring monitoring.
• Infections: increased susceptibility to common bacterial or viral infections.
• Tremor: mild shaking of hands or limbs.

Serious or Rare Side Effects

• Leukopenia: significant reduction in white blood cells.
• Anemia: decreased red blood cell count causing fatigue.
• Severe infections: opportunistic infections such as CMV or fungal disease.
• Malignancy: increased risk of certain cancers with long‑term use.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Pregnancy loss: teratogenic effects leading to fetal harm.

Careful monitoring and patient counseling are essential when using Mycofenolzuur Accord.

• Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia.
• Assess renal function: adjust therapy based on creatinine clearance and kidney health.
• Avoid use in pregnancy: category X indicates known fetal risk; contraindicated.
• Avoid live vaccines: immunosuppression can lead to vaccine‑derived infection.
• Adjust dose in hepatic impairment: consider reduced dosing for patients with liver disease.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Mycofenolzuur Accord can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Live vaccines: increased risk of infection due to immunosuppression.
• Azathioprine: additive bone‑marrow suppression leading to severe cytopenias.
• Rituximab: enhanced immunosuppressive effect, raising infection risk.

Moderate Interactions (Monitor Closely)

• Antacids (e.g., aluminum hydroxide): may reduce mycophenolic acid absorption.
• CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations, requiring dose adjustment.
• CYP3A4 inducers (e.g., rifampin): decrease drug levels, potentially reducing efficacy.